Several hedge funds are gearing up for another biopharma IPO, hoping it will be as successful as a handful of others this year.
Carmot Therapeutics filed plans on November 17 to go public, according to a regulatory filing. It has not yet indicated the number of shares it plans to sell or the anticipated price range.
